Kevin Grogan
Managing Editor
Kevin Grogan has been writing about pharmaceuticals for over twenty years in roles that have included online editor for PharmaTimes. After four years freelancing, which involved writing for all the principal titles in the sector, as well as consultancy work with major pharmaceutical companies, he joined Scrip as Managing Editor, Europe, Commercial in the summer of 2017.
Covering all aspects of the pharma industry, Kevin has interviewed pretty much all the leading figures in the sector, both in the UK and globally. A regular attendee at financial and medical conferences worldwide (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss events in the pharmaceutical industry.
Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at the Catholic weekly newspaper The Universe and also contributed articles to the likes of The Independent and the Manchester Evening News on football.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Kevin Grogan
Financial Transparency Concerns Over Patient Groups Advising NICE
England and Wales' cost-effectiveness agency has been urged to review its disclosure policy in a BMJ report which calls on NICE to probe the financial transparency of patient organizations that contribute to reimbursement assessments.
Loxo Links And Colorectal Cancer Data Put Array In M&A Spotlight
Following Lilly's proposed acquisition of Loxo, other possible takeover targets in the precision medicine field have emerged and Array, armed with more positive data on its colorectal cancer triplet, is near the top of the list.
AZ Management Shake-Up Sees CMO Bohen Exit
Sean Bohen is to join Bahija Jallal, Mark Mallon and Ludovic Helfgott in leaving AstraZeneca as the company transitions to a new organizational structure announced last week by CEO Pascal Soriot.
Rovi and Recordati Deemed Top Picks By Analyst
The team at Jefferies believe that the Spanish and Italian firms, as well as Hikma, are looking like good bets for the year ahead.
Novartis Gets NICE Headache From Aimovig Knockback
The cost-effectiveness watchdog is worried about the cost of Novartis's once-monthly first-in-class migraine drug and is not convinced it is more effective than Allergan’s Botox, which can require up to 40 injections into the head and neck.
Immunic of Germany Set For Nasdaq After Merger With Failed Vital Therapies
The demise of Vital after a crushing late-stage failure has given Immunic the opportunity to cross the Atlantic and grow its business and pipeline.